Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 by Fadel, Raef et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Internal Medicine Articles Internal Medicine 
5-19-2020 
Early Short Course Corticosteroids in Hospitalized Patients with 
COVID-19 
Raef Fadel 
Henry Ford Health System, RFADEL2@hfhs.org 
Austin R. Morrison 
Henry Ford Health System, amorri14@hfhs.org 
Amit Vahia 
Henry Ford Health System, avahia1@hfhs.org 
Zachary R. Smith 
Henry Ford Health System, ZSMITH1@hfhs.org 
Zohra Chaudhry 
Henry Ford Health System, ZChaudh2@hfhs.org 
See next page for additional authors 
Follow this and additional works at: https://scholarlycommons.henryford.com/internalmedicine_articles 
Recommended Citation 
Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, Miller J, Kenney RM, Alangaden G, and 
Ramesh MS. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis 
2020. 
This Article is brought to you for free and open access by the Internal Medicine at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Internal Medicine Articles by an authorized administrator 
of Henry Ford Health System Scholarly Commons. 
Authors 
Raef Fadel, Austin R. Morrison, Amit Vahia, Zachary R. Smith, Zohra Chaudhry, Pallavi Bhargava, Joseph B. 
Miller, Rachel M. Kenney, George Alangaden, and Mayur Ramesh 
This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/
internalmedicine_articles/286 
M A J O R  A R T I C L E
Early Short Corticosteroids With COVID-19 • cid 2020:XX (XX XXXX) • 1
Clinical Infectious Diseases
Early Short-Course Corticosteroids in Hospitalized 
Patients With COVID-19
Raef Fadel,1,a Austin R. Morrison,2,a  Amit Vahia,3 Zachary R. Smith,2 Zohra Chaudhry,3 Pallavi Bhargava,3 Joseph Miller,4 Rachel M. Kenney,2  
George Alangaden,3 and Mayur S. Ramesh3; Henry Ford COVID-19 Management Task Force#
1Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA, 2Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA, 3Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA, and 
4Emergency Medicine, Henry Ford Hospital, Detroit, Michigan, USA
Background. There is no proven antiviral or immunomodulatory therapy for coronavirus disease 2019 (COVID-19). The di-
sease progression associated with the proinflammatory host response prompted us to examine the role of early corticosteroid therapy 
in patients with moderate to severe COVID-19.
Methods. We conducted a single pretest, single posttest quasi-experiment in a multicenter health system in Michigan from 12 
March to 27 March 2020. Adult patients with confirmed moderate to severe COVID were included. A protocol was implemented 
on 20 March 2020 using early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days. 
Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary composite endpoint of escala-
tion of care from ward to intensive care unit (ICU), new requirement for mechanical ventilation, and mortality. All patients had at 
least 14 days of follow-up.
Results. We analyzed 213 eligible subjects, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively. The 
composite endpoint occurred at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005). This treatment 
effect was observed within each individual component of the composite endpoint. Significant reduction in median hospital length 
of stay was also observed in the early corticosteroid group (5 vs 8  days, P < .001). Multivariate regression analysis demonstrated an 
independent reduction in the composite endpoint at 14-days controlling for other factors (adjusted odds ratio: 0.41; 95% confidence 
interval, .22 – .77). 
Conclusions. An early short course of methylprednisolone in patients with moderate to severe COVID-19 reduced escalation 
of care and improved clinical outcomes.
clinical Trials Registration. NCT04374071.
Keywords.  Corticosteroids; outcomes; COVID-19; SARS-COV-2; coronavirus.
BACKGROUND
As of 9 April 2020, the United States has over 400  000 cases 
of confirmed coronavirus disease 2019 (COVID-19) caused by 
the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1]. Most patients will have mild illness, but older per-
sons and those with comorbidities may develop severe disease 
necessitating hospitalization and time in the intensive care unit 
(ICU) [2, 3]. The disease pathophysiology presents in 2 dis-
tinct overlapping phases, the initial pathogenic viral response 
followed by host inflammatory response with grades of severity 
associated with distinct clinical findings [4, 5]. The patholog-
ical progression in severe COVID-19 includes an excessive 
and unregulated proinflammatory cytokine storm resulting 
in immunopathological lung injury, diffuse alveolar damage 
with the development of acute respiratory distress syndrome 
(ARDS), and death [6–9].
In the absence of any proven antiviral therapy, the current 
clinical management is primarily supportive care, supple-
mental oxygen, and mechanical ventilatory support [1, 10]. 
Adjunctive therapy with immunomodulatory agents targeting 
the inflammatory cytokine storm are being evaluated [5, 10]. 
Studies of corticosteroid therapy for phylogenetically sim-
ilar coronavirus infections showed no benefit and potential 
harm [11]. Despite the frequent use in treating patients with 
COVID-19 in China, the role of corticosteroids is undefined 
[3, 5, 10–13]. A more recent observational study reported im-
proved outcomes in patients with COVID-associated ARDS 
that received corticosteroids [14].
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We postulated that early treatment with a short course of cor-
ticosteroids in patients with COVID-19 may attenuate the exces-
sive host respiratory and systemic inflammatory responses. We 
report the clinical characteristics and early outcomes of patients 
with COVID-19 receiving short courses of methylprednisolone.
METHODS
Study Population
Consecutive patients hospitalized from 12 March 2020 through 
27 March 2020 were eligible for inclusion if they were ≥18 years, 
had confirmed COVID-19 infection, with radiographic evi-
dence of bilateral pulmonary infiltrates, and required oxygen 
by nasal cannula, high-flow nasal cannula (HFNC), or mechan-
ical ventilation. Patients were excluded if they were transferred 
from an out-of-system hospital, died within 24 hours of pre-
sentation to the emergency department (ED), or were admitted 
for <24 hours. A confirmed case of COVID-19 was defined as 
a patient that had a positive reverse-transcription polymerase 
chain reaction (RT-PCR) assay for SARS-CoV-2 in a nasopha-
ryngeal sample tested by the Michigan Department of Health 
and Human Services (MDHHS) or the Henry Ford Health 
System (HFHS) centralized clinical microbiology laboratory. 
Beginning 16 March 2020, testing for hospitalized patients was 
performed by the centralized clinical microbiology laboratory.
Patients were risk stratified by severity of symptoms on 
presentation to the hospital as mild, moderate, or severe 
COVID-19. Patients without hypoxia or exertional dyspnea 
were considered to have mild COVID-19. Patients with mild 
COVID-19 were treated with symptom relief only and not ad-
mitted to the hospital. Patients who presented with infiltrates on 
chest radiography and required supplemental oxygen by nasal 
cannula or HFNC were classified as having moderate COVID-
19. Patients who had respiratory failure requiring mechanical 
ventilation were classified as having severe COVID-19.
Study Design
This was a multicenter quasi-experimental study at HFHS, com-
posed of 5 hospitals in southeast and south-central Michigan. 
The study was approved by the institution’s Investigational 
Review Board (13739) with waiver of consent. Patients in the 
standard of care (SOC) group from 12 March 2020 through 19 
March 2020 were compared to an early corticosteroid group that 
included patients from 20 March 2020 through 27 March 2020.
Patients in both study groups received standard care, com-
posed of supplemental oxygen, HFNC, invasive ventilation, 
antibiotic agents, antiviral agents, vasopressor support, and renal-
replacement therapy, as determined by the primary team. Patients 
who progressed to ARDS were managed with SOC [15].
Intervention Standard of Care
Patients with moderate or severe disease who presented to HFHS 
within the first week of the COVID epidemic in Detroit were 
initially treated with supportive care with or without a combina-
tion of lopinavir-ritonavir and ribavirin or hydroxychloroquine ac-
cording an institutional guideline developed by Infectious Diseases 
Physicians and Pharmacists. The institutional guidelines were devel-
oped by consensus, and based on the available literature, experience 
from Wuhan, China, and other centers around the world affected 
by COVID-19 before Michigan. Intravenous (IV) remdesivir com-
passionate use was requested for eligible mechanically ventilated 
patients. On 17 March 2020 lopinavir-ritonavir with ribavirin was 
removed from the COVID-19 institutional protocol [16]. Steroids 
were considered on a case-by-case basis.
Early Corticosteroid Group
As a result of observed poor outcomes, clinical rationale based 
on immunology, clinical course of COVID-19, and more recently 
best available evidence, the HFHS early corticosteroid protocol 
was developed (Supplementary Materials) [14, 15, 17]. We hy-
pothesized that early corticosteroids would combat the inflamma-
tory cascade leading to respiratory failure, ICU escalation of care, 
and mechanical ventilation. The early corticosteroid protocol 
was incorporated in the institutional COVID-19 guidelines on 
20 March 2020. Patients with confirmed influenza infection were 
not recommended to receive early corticosteroids. The decision to 
prescribe hydroxychloroquine and early corticosteroids was at the 
discretion of the primary medical team.
Moderate COVID-19 was treated with hydroxychloroquine 
400 mg twice daily for 2 doses on day 1, followed by 200 mg 
twice daily on days 2–5. Patients with moderate COVID-19 who 
required 4 liters or more of oxygen per minute on admission, or 
who had escalating oxygen requirements from baseline, were 
recommended to receive IV methylprednisolone 0.5 to 1 mg/
kg/day in 2 divided doses for 3 days. Patients who required ICU 
admission were recommended to receive the above regimen of 
hydroxychloroquine and IV methylprednisolone 0.5 to 1  mg/
kg/day in 2 divided doses for 3–7 days. ICU patients were also 
evaluated for tocilizumab on a case-by-case basis. Oral switch 
was performed to prednisone at a ratio of 1 to 1 when deter-
mined clinically appropriate by the primary medical team.
Data Collection
Data were ascertained from each institution’s electronic medical 
record and recorded in a standardized electronic case report 
form. Demographic data, information on clinical symptoms 
or signs at presentation, and laboratory and radiologic results 
during admission  were collected. All laboratory tests and ra-
diologic assessments, including plain chest radiography and 
computed tomography of the chest, were performed at the dis-
cretion of the treating physician.
Study Definitions
We ascertained coexisting conditions from electronic med-
ical record and physician documentation. The National Early 
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Warning Score (NEWS) was collected to evaluate baseline ill-
ness severity based on vital signs obtained in the ED [18]. 
Additionally, the quick Sequential Organ Failure Assessment 
was used to evaluate severity of illness of included patients 
based on ED vitals and examination [19]. All patients were fol-
lowed for at least 14 days after initial presentation. Patient data 
were censored on 9 April 2020.
OUTCOME MEASURES
Primary Endpoint
The primary composite endpoint was escalation to an ICU 
from a general medical unit, progression to respiratory failure 
requiring mechanical ventilation after hospital admission, or 
in-hospital all-cause mortality. Patients directly admitted to the 
ICU from the emergency room were evaluated for the latter 2 
outcomes, and those requiring mechanical ventilation in the 
emergency room were evaluated for mortality.
Secondary Endpoints
Secondary endpoints included development and severity of 
ARDS, days to ventilator liberation, shock, acute kidney injury 
(AKI), and length of hospital stay (LOS). LOS was reported 
only for patients who were discharged alive within the 14-day 
minimum follow-up period. ARDS was diagnosed and classi-
fied according to the Berlin definition [20]. AKI was diagnosed 
according to the Kidney Disease: Improving Global Outcomes 
definition [21].
Statistical Analysis
Continuous variables were reported as median and interquar-
tile range (IQR) and compared using the Mann-Whitney test or 
t-test, as appropriate. Categorical data were reported as number 
and percentage (no., %) and compared using the χ 2 test or Fisher 
exact test, as appropriate. No imputation was made for missing 
data points. The sample size was derived from all eligible con-
secutive hospitalized patients during the study period. A 2-sided 
α < 0.05 was considered statistically significant. Bivariate and 
multivariable logistic regression analysis was planned a priori 
to test the association between the composite endpoint and ex-
posure to the corticosteroid protocol. Covariates in the bivariate 
analysis with a P-value <.2 and clinical rationale were included 
in a multivariable regression model that was restricted to a 
subject-to-variable ratio of 10:1. To evaluate the implementa-
tion timing of the in-house RT-PCR SARS-CoV-2 testing a post 
hoc sensitivity analysis were conducted on the composite out-
come. A nonequivalent dependent variable, receipt of, and time 
to empiric antibiotic therapy for pneumonia, was utilized to ac-
count for potential maturation in the management of COVID-
19. Statistical analysis was performed using IBM SPSS version 
25 (Chicago, IL) and SAS 9.4 (Cary, NC).
RESULTS
Two-hundred and fifty consecutive patients were evaluated for 
inclusion. Ten were hospitalized for ≤24 hours, 23 did not re-
quire oxygen by nasal cannula, HFNC, or mechanical ventila-
tion, and 4 expired within 24 hours of admission (Figure 1). 
Two-hundred and thirteen patients were included, 81 (38%) in 
the SOC group and 132 (62%) in the early corticosteroid group. 
The median age of the SOC group and early corticosteroid group 
was 64 (IQR: 51.5, 73.5) and 61 (IQR: 51, 72) years, respectively. 
Black patients comprised 61.7% of the SOC group and 79.5% 
of the early corticosteroid group (P =  .005). Of the comorbid 
conditions evaluated, chronic obstructive pulmonary disease 
was more frequent in the SOC group compared to the early 
corticosteroid group (18.5% vs 9.1%; P = .045). The presenting 
COVID-19 symptoms, baseline severity of illness, and other 
demographics are presented in Table 1. One patient had a con-
comitant influenza infection in the early corticosteroid group.
Overall, corticosteroids use was 56.8% and 68.2% in the SOC 
group and early corticosteroid group, respectively (P  =  .094). 
The early corticosteroid group had a greater proportion of cor-
ticosteroids initiated within 48 hours of presentation (12.4% 
vs 41.7%, P < .001), with a median time to initiation of 2 days 
(IQR: 1–3, range 0–8) as compared to 5 days (IQR: 3–7, range 
1–9) in the SOC. The median time to hydroxychloroquine initi-
ation was greater in the SOC group compared to the early cor-
ticosteroid group (3 [IQR: 1, 4] vs 1 [IQR: 0, 2] days, P < .126). 
Additional treatment characteristics are described in Table 2.
The primary composite endpoint occurred at a significantly 
lower rate in the early corticosteroid group compared to the 
SOC group (34.9% vs 54.3%, P  =  .005). A  significant reduc-
tion in each of primary composite endpoints was also noted 
(Table 3). In the sensitivity analysis subgroup, after the imple-
mentation of the in-house RT-PCR SARS-CoV-2 testing, 34.9% 
(46 of 132 patients) and 55% (33 of 60 patients) experienced the 
primary composite endpoint in the early corticosteroid group 
and SOC group, respectively (P  =  .009). After adjustment for 
male sex, NEWS of ≥7, and age ≥60, early corticosteroid in-
itiation was independently associated with a reduction in the 
composite endpoint at 14 days (adjusted odds ratio: 0.41; 95% 
confidence interval [CI], (.22  – .77) (Table S2, Supplemental 
Materials).
The median LOS was significantly reduced from 8 days in 
the SOC group, to 5  days in the early corticosteroid group 
(P <  .001). ARDS occurred in 38.3% and 26.6% in the SOC 
group and early corticosteroid group, respectively (P =  .04). 
Outcomes at 14 days also included 9 (11.1%) of SOC patients 
remaining admitted as compared to 26 (19.7%) of early cor-
ticosteroid patients. Table  3 describes additional outcomes 
before and after implementation of the early corticosteroid 
protocol.
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Table 2. Treatments Received by Groups
Treatment
Total  
(n = 213) SOC (n = 81) Early CG (n = 132) P value
Antimicrobials
 Empiric antibiotic prescribed for pneumonia, no. (%) 163 (76.5) 65 (80.2) 98 (74) .316
 Median time to empiric antibiotics (IQR), d 1 (0–1) 1 (0–1) 0 (0–1) .631
 Median duration of antimicrobials (IQR), d 4 (2–5) 5 (3–5) 3 (2–5) .009
 Hydroxychloroquine use, no. (%) 161 (75.6) 57 (70.4) 104 (78.8) .167
 Median time to hydroxychloroquine initiation (IQR), d 2 (1–3) 3 (1–4) 1 (0–2) .126
 Lopinavir/ritonavir and ribavirin use, no. (%) 10 (4.7) 9 (11.1) 1 (0.76) .001
 Remdesivir use, no. (%) 5 (2.3) 5 (6.2) 0 (0) .004
 Tocilizumab use, no. (%) 14 (6.6) 8 (10.1) 6 (4.5) .126
Corticosteroid treatment
 Median time to steroid initiation from admission (IQR), d 2 (1–4) 5 (3–7) 2 (1–3) <.001
 Corticosteroids received in first 48 h, no. (%) 65 (30.5) 10 (12.4) 55 (41.7) <.001
 Corticosteroids received at any time, no. (%)a 136 (63.8) 46 (56.8) 90 (68.2) .094
 Methylprednisolone use, no. (%) 129 (94.9) 43 (93.5) 86 (95.5) .688
 Median methylprednisolone dose (IQR), mg 40 (40–50) 40 (40–50) 40 (35–50) .851
 Oral prednisone switch, no. (%) 7 (5.4) 5 (11.6) 2 (2.3) .041
 Median duration of corticosteroids (IQR), db 3 (3-3) 3 (3-3) 3 (3-3) .812
Abbreviations: CG, corticosteroid group; IQR, interquartile range; SOC, standard of care.
aRefer to Figure S1, supplemental materials for description of timing.
b29 patients received greater than 3 days; Early corticosteroid group 20 (22.2), 9 SOC (19.5).
Table 1. Baseline Demographics and Clinical Characteristics of Study Patients
Characteristics
Total  
(n = 213) SOC (n = 81) Early CG (n = 132) P value
Demographics
 Median age (IQR), y 62 (51–62) 64 (51.5–3.5) 61 (51–72) .400
 Male sex, no. (%) 109 (51.2) 41 (50.6) 68 (51.5) .899
 Black race, no. (%) 155 (72.8) 50 (61.7) 105 (79.5) .004
 Median body mass index (IQR) - kg/m2 32 (27.3–38.7) 30 (25–39) 33.2 (28.9–38.5) .007
Coexisting conditions, no. (%)
 Asthma 33 (15.5) 16 (19.8) 17 (12.9) .180
 Chronic kidney disease 98 (46) 41 (51.9) 57 (43.5) .240
 Chronic obstructive pulmonary disease 27 (12.7) 15 (18.5) 12 (9.1) .045
 Congestive heart failure 26 (12.2) 10 (12.5) 16 (12.2) .951
 Coronary artery disease 38 (17.8) 18 (22.2) 20 (15.2) .192
 Diabetes 105 (49.3) 37 (45.7) 68 (51.5) .411
 Hypertension 158 (74.2) 62 (76.5) 96 (72.7) .925
 Malignancy 24 (11.3) 11 (13.6) 13 (9.9) .405
 Smoking history 88 (41.3) 40 (49.4) 48 (36.4) .062
Symptoms
 Cough, no. (%) 158 (74.2) 62 (76.5) 96 (72.7) .536
 Fever, no. (%) 150 (70.4) 57 (70.4) 93 (70.5) .989
 Myalgia, no. (%) 85 (39.9) 32 (39.5) 53 (40.2) .926
 Shortness of breath, no. (%) 148 (69.5) 50 (61.7) 98 (74.2) .054
 Median duration of symptoms (IQR), d 5 (3–7) 5 (2–7) 6 (3–7) .107
Severity of illness in ED
 Median qSOFA (IQR) 1 (0–1) 1 (0–1) 1 (0–1) .850
 Median NEWS (IQR) 7 (4–10) 7 (4–10) 7 (4–9) .668
 Requiring mechanical ventilation in ED, no. (%) 22 (10.3) 10 (12.3) 12 (9.1) .448
 Direct admission to ICU, no. (%) 26 (12.2) 11 (13.6) 15 (11.4) .631
Abbreviations: CG, corticosteroid group; ED, emergency department; ICU, intensive care unit; IQR, interquartile range; NEWS, National Early Warning Score; qSOFA, quick Sequential Organ 
Failure Assessment; SOC, standard of care.
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DISCUSSION
In this quasi-experimental study, hospitalized patients with 
moderate to severe COVID-19 that received an early short 
course of methylprednisolone had a reduced rate of the pri-
mary composite endpoint of death, ICU transfer, and mechan-
ical ventilation, with a number needed to treat of 8 to prevent 
1 patient transfer for mechanical ventilation. The reduction in 
ICU transfer and requirement for mechanical ventilation repre-
sents a potential intervention to reduce critical care utilization 
during the COVID-19 pandemic [22, 23]. The median reduc-
tion of hospital LOS by 3  days observed with the use of cor-
ticosteroids could positively impact hospital capacity during the 
COVID-19 surge.
Corticosteroids are not routinely recommended in patients 
with COVID-19 without an alternate indication or presence 
of ARDS [11, 15, 24]. Data are conflicting; corticosteroid use 
in previous viral respiratory illnesses has demonstrated de-
layed viral clearance and increased mortality [11, 25]. On the 
Table 3. Outcomes in Standard of Care and Early Corticosteroid Group
Outcomes SOC (n = 81) Early CG (n = 132) Odds Ratio (CI) P value
Primary outcome 
Primary composite outcome, no. (%) 44 (54.3) 46 (34.9) .45 (.26–.79) .005
 Death, no. (%) 21 (26.3) 18 (13.6) .45 (.22–.91) .024
 Respiratory failure requiring mechanical ventilation, no. (%)a 26 (36.6) 26 (21.7) .47 (.25–.92) .025
 Escalation from GMU to ICU, no. (%)b 31 (44.3) 32 (27.3) .47 (.25–.88) .017
Secondary outcomes
Overall mechanical ventilation, no. (%) 36 (44.4) 38 (28.8) .51 (.28–.90) .020
ARDS, no. (%) 31 (38.3) 33 (26.6)  .040
 Mild 3 (3.7) 1 (0.76)  .125
 Moderate 8 (9.9) 9 (6.8)  .307
 Severe 20 (24.7) 23 (17.4)  .201
Median duration of mechanical ventilation (IQR), d 8 (4–13) 7 (4–9)  .558
Median time to extubation (IQR), d 8 (4–13) 7 (4–9)  .558
Shock, no. (%) 19 (23.5) 17 (12.6)  .069
Acute kidney injury, no. (%) 42 (51.9) 59 (44.7)  .310
Median hospital length of stay (IQR), d 8 (5–14) 5 (3–7)  <.001
Discharged from hospital, no. (%) 51 (62.2) 88 (66.7)  .584
Remain hospitalized, no. (%) 9 (11.1) 26 (19.7)  .102
Remain intubated, no. (%) 7 (8.6) 13 (9.8)  .771
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; CG, corticosteroid group; GMU, general medical unit; ICU, intensive care unit; IQR, interquartile range; 
SOC, standard of care.
aA total of 10 and 12 patients were not included in this analysis because they required mechanical ventilation in the emergency department in the SOC and early corticosteroid groups, 
respectively.
bA total of 11 and 15 patients were not included in this analysis because they were directly admitted to the ICU in the SOC and early corticosteroid groups, respectively.
250 paents underwent 
screening 
37 excluded
10 hospitalized < 24 hours
23 did not require supplemental oxygen
4 expired within 24 hours of presentaon
0 transfer from out-of-system hospital
213 included
132 admied to early 
corcosteroid group
81 admied to standard of 
care group
Figure 1. Number of patients screened and included in the trial.
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contrary, short-course corticosteroids in some reports are ben-
eficial and safe in critically ill patients with SARS-CoV-2 and 
were not found to be an independent risk factor of prolonged 
viral RNA shedding [17, 26, 27]. These discordant findings 
may be explained by the observational nature of the studies, 
heterogeneity in patient acuity, inconsistent dosing regimens 
and duration, and timing of initiation of therapy [10, 17]. 
Corticosteroids were used in 11–35% of nonsevere and 45–72% 
of severe COVID-19 cases in China; however, the benefits and 
risks remain undefined [2, 6, 12–14]. A mortality benefit (hazard 
ratio, 0.38; 95% CI, .20–.72) with the use of methylprednisolone 
was reported in 1 retrospective cohort study of COVID-19 pa-
tients with ARDS [14].
COVID-19 can progress from mild to severe illness charac-
terized by an initial viral infection phase followed by pulmo-
nary inflammation, and then a hyper-inflammation phase [4, 6, 
9]. The pulmonary phase is associated with progressive dyspnea 
and radiographic findings of pneumonia [4]. Symptom onset 
to dyspnea and ARDS development occurs between a median 
of 5–7 days and 8–12 days, respectively [6, 12, 28]. The present 
study findings support that timing is key. An early course of 
corticosteroid, specifically methylprednisolone, at the onset of 
dyspnea, may attenuate progression to the hyper-inflammation 
phase that requires escalation of care in patients with COVID-
19. In this study, 3 days of early corticosteroids were adminis-
tered at a median 2 days into hospitalization and 8 days from 
symptom onset. However, the administration of a 3-day course 
of corticosteroids later in the disease course (median 5 days after 
hospitalization), as occurred in our SOC group, did not appear 
to confer the same benefit. Hydroxychloroquine with or without 
azithromycin, remdesivir, and lopinavir/ritonavir with ribavirin 
were prescribed at similar frequency between groups. These 
agents have demonstrated mixed efficacy results for COVID-19 
in placebo controlled-trials, with hydroxychloroquine being the 
most promising at this time [10]. Immunomodulatory agents, 
such as tocilizumab, were infrequently used in this study.
This study has several limitations. Given the pandemic na-
ture of the disease, a pragmatic quasi-experimental design was 
used, and there are some differences in the baseline character-
istics of the comparator groups. The potential for regression 
to the mean and maturation is an inherent limitation to all 
quasi-experiments. On 16 March 2020, rapid on-site RT-PCR 
testing for SARS-CoV-2 testing was implemented, and some of 
the SOC group experienced delayed diagnosis and treatment. 
However, the observed association was unchanged in the sen-
sitivity analysis. A nonequivalent dependent variable, empiric 
antibiotic therapy for pneumonia, suggested no difference in 
management of COVID-19. Some of the SOC group received 
corticosteroids after initiation of the updated COVID-19 in-
stitutional treatment protocol. Steroids initiated in this group 
were started significantly later. Additionally, guideline adher-
ence in the early corticosteroid group was not universal, and 
may have been subject to channeling bias. Prone ventilation was 
attempted in a single SOC group patient and then not utilized 
again until late March. This may have impacted development of 
the primary outcome in the subset patients who required me-
chanical ventilation. Finally, the study has a limited follow-up 
period of 14 days and may be subject to lead-time bias, similar 
to other recent reports. As of 9 April 2020, 51 (62.9%) of pa-
tients in the SOC cohort and 88 (66.7%) of patients in the early 
corticosteroid cohort were discharged from the hospital. As a 
result, outcomes for those patients are not known. Anecdotally, 
we observed hyperglycemia but no severe corticosteroid related 
adverse effects (ie, gastrointestinal hemorrhage), and data col-
lection is ongoing.
In conclusion, early use of a short course of 
methylprednisolone, an inexpensive and readily available agent, 
in patients with moderate to severe COVID-19 may prevent 
progression of disease and improve outcomes. These findings 
are crucial given the ongoing COVID-19 pandemic and ICU 
bed and mechanical ventilator shortages. Research is urgently 
needed to further define the role of corticosteroids in patients 
with COVID-19 at a high risk of clinical deterioration, iden-
tified early in the disease course using prognostic markers or 
clinical prediction tools.
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